Eisai and Biogen are one step away ... An under-the-skin formulation would make it simpler and easier for patients and care partners to administer the therapy, along with reducing visits to ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...

Transitioning MS care to quantitative medicine Despite advances made in MS, patient assessments in medical practice remain qualitative and nonstandardized. Biogen has recognized the importance of ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly ...

Telehealth company Talkiatry has partnered with Biogen to expand its support service ... but getting access to care can be complex, leading to delayed diagnosis and treatment.

Anthony Noto FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI) for weekly ...